Â鶹´«Ã½Ó³»­

Â鶹´«Ã½Ó³»­

Explore the latest content from across our publications
Join The Â鶹´«Ã½Ó³»­

Log In

Forgot Password?
Create New Account

Loading... please wait

Abstract Details

MOG Optic Neuritis: Atypical Presentations and Disease Spectrum at a Tertiary Centre, Calgary, Alberta
Multiple Sclerosis
P12 - Poster Session 12 (12:00 PM-1:00 PM)
9-022
To review the spectrum of MOG optic neuritis presentations, characteristics and treatment responses with a focus on atypical cases.
Recurrent optic neuritis is a known presentation of MOG antibody disease (MOGAD). Patients are typically younger than their AQP4 antibody positive counterparts, with a more balanced ratio of females to males and Caucasians to non-Caucasians.  One of the hallmarks of MOGAD is the excellent response to high-dose corticosteroids.  However, as we learn more about MOGAD, a wider spectrum of presentations and therapeutic responses are coming to light.  In Calgary, Alberta, we have noted such heterogeneity in our MOG optic neuritis cohort.
The authors have collected MOG optic neuritis cases since the cell-based assay became available at our institution.  Initial case review has revealed several patients that would be deemed "atypical" by current MOG definitions, including several patients presenting with bilateral, severe and treatment-refractory optic neuritis.
A full review of identified MOG optic neuritis patients will be presented, with a specific focus on atypical cases, including two Asian men, both in their 40's, with bilateral and severe optic neuritis that required multiple rescue therapies on top of high-dose corticosteroids, including repeated plasmapheresis and rituximab.
Our understanding of the phenotypes, characteristics, and treatment responses in MOGAD, and MOG optic neuritis specifically, are continually evolving.  With a better appreciation of the range of disease manifestations, we will be able to improve and tailor treatment regimens more efficiently with better patient outcomes.  
Authors/Disclosures
Jodie Burton, MD, FÂ鶹´«Ã½Ó³»­
PRESENTER 		Dr. Burton has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Roche. Dr. Burton has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Novartis. Dr. Burton has received personal compensation in the range of $0-$499 for serving as a Consultant for Horizon. The institution of Dr. Burton has received research support from Roy and Joan Allen Professorship for Sight. Dr. Burton has a non-compensated relationship as a Advisor with CADTH that is relevant to Â鶹´«Ã½Ó³»­ interests or activities. Dr. Burton has a non-compensated relationship as a Advisor with Alexion that is relevant to Â鶹´«Ã½Ó³»­ interests or activities. Dr. Burton has a non-compensated relationship as a Advisor with Horizon that is relevant to Â鶹´«Ã½Ó³»­ interests or activities. Dr. Burton has a non-compensated relationship as a Â鶹´«Ã½Ó³»­al Chair with EMD Serono that is relevant to Â鶹´«Ã½Ó³»­ interests or activities.
Katayoun Alikhani, MD (South Health Campus) Dr. Alikhani has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Apotex, Biogen, Bristol Myers Squibb, EMD Serono, Novartis, Roche, Sanofi Genzyme.
Fiona E. Costello, MD (Fiona Costello Professional Corporation) Dr. Costello has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Alexion. Dr. Costello has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Roche. Dr. Costello has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Novartis. Dr. Costello has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Alexion. Dr. Costello has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Accure Therapeutics. Dr. Costello has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for the Sumaira Foundation.